Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo (C-OPTIMISE)
A Multicenter, Open-label (Part A) Followed by a Randomized, Double-blind, Parallel-group, Placebo Controlled Study (Part B) to Evaluate Maintenance of Remission in Subjects With Active Axial Spondyloarthritis (axSpA) Receiving Either Certolizumab Pegol 200 mg Q2W or 200 mg Q4W as Compared to Placebo
Sponsor: Parexel
Listed as NCT02505542, this PHASE3 trial focuses on Ankylosing Spondylitis and Axial Spondyloarthrithis and remains completed. Sponsored by Parexel, it has been updated 22 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
22 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 17 earlier versions
-
May 2020 — Aug 2020 [monthly]
Completed PHASE3
-
Aug 2019 — May 2020 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Apr 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE3
-
Mar 2019 — Apr 2019 [monthly]
Active Not Recruiting PHASE3
-
Feb 2019 — Mar 2019 [monthly]
Active Not Recruiting PHASE3
-
Jan 2019 — Feb 2019 [monthly]
Active Not Recruiting PHASE3
-
Dec 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE3
-
Oct 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE3
-
Sep 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE3
-
Aug 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE3
-
Jul 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Jun 2017 — Apr 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
May 2017 — Jun 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — May 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Jul 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Parexel
- UCB BIOSCIENCES GmbH
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amsterdam, Netherlands , Ankara, Turkey (Türkiye) , Austin, United States , Berlin, Germany , Bialystok, Poland , Bochum, Germany , Brandon, United States , Brasov, Romania , Brno, Czechia , Bruntál, Czechia and 76 more locations